Pharma Company BioCanCell Raises $25 million, Plans to Go Public in the U.S.
The company said it will use the funding for clinical trials of BC-819, a drug being designed to treat early stage bladder cancer
17:1423.01.18
BioCanCell Ltd., a biopharmaceutical company based in Jerusalem and Cambridge, Massachusetts, announced on Tuesday it has signed a term sheet for an investment of $25 million. The company also said it would seek to get listed on a U.S. stock exchange in 2018.
Lab (illustration). Photo: Bloomberg
For daily updates, subscribe to our newsletter by clicking here.
The investment will come out to 1.6 shekels ($ 0.47) per share, a 14% markup over the market price. The deal reflects a company valuation of $51 million, BioCanCell said in a statement.
Lab (illustration). Photo: Bloomberg
The company said it will use the funding for clinical trials of BC-819, a drug being designed to treat early stage bladder cancer.
BioCanCell did not identify the investors but said the lead investor will provide $7 million of its funds and up to $8 million in commitments from other investors.
Founded in 2004, BioCanCell is controlled by Israel-based Clal Biotechnology Industries Ltd.
